Regulatory Status BPC-157 is not an FDA-approved drug for any indication and has not been evaluated by the FDA for safety or efficacy
Description Indication B1, B6 and B12 deficiency syndrome, sciatica, lumbago, trigeminal neuralgia, facial paralysis, optic neuritis, Diabetic neuropathy, Peripheral neuralgia, Myalgia Adult Dose Adult Tablet: 1-2 tablets three times daily
It extends the half-life of your natural GHRH signaling, creating a sustained elevation in GH pulsatility rather than a single spike
The Certificate of Analysis confirms purity, verifies molecular identity, and carries a unique batch number for full traceability
Potential Benefits & Side Effects What preclinical literature describes